Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

51.67
-0.8650-1.65%
Volume:308.44K
Turnover:15.91M
Market Cap:4.92B
PE:-9.25
High:51.95
Open:51.36
Low:51.22
Close:52.53
52wk High:78.48
52wk Low:30.04
Shares:95.30M
Float Shares:90.53M
Volume Ratio:2.20
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.5830
EPS(LYR):-4.3416
ROE:-25.33%
ROA:-13.28%
PB:2.57
PE(LYR):-11.90

Loading ...

More Drugs to Fight High Cholesterol Are Emerging -- WSJ

Dow Jones
·
Nov 09

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

GlobeNewswire
·
Nov 09

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

GlobeNewswire
·
Nov 08

Wedbush Adjusts CRISPR Therapeutics Price Target to $9 From $13, Maintains Outperform Rating

MT Newswires Live
·
Nov 05

CRSP, BEAM, ROKU, SOFI: Cathie Wood Pours $17 Million into Biotech Stocks, Trims Tech Favorites

TIPRANKS
·
Nov 05

Caribou Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Nov 04

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Benzinga
·
Nov 04

ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB® Technology

prnewswire
·
Oct 29

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 29

CRISPR Therapeutics (CRSP) Is Down 11.2% After Intellia Pauses Trials Due to Safety Event Has The Bull Case Changed?

Simply Wall St.
·
Oct 28

Vertex Pharmaceuticals Advances with Promising CRISPR Gene-Editing Study

TIPRANKS
·
Oct 28

Caribou Biosciences Advances CRISPR-Edited CAR-T Therapy in Lymphoma Study

TIPRANKS
·
Oct 28

Intellia Therapeutics: Buy Rating Affirmed Amid Strategic Developments and CRISPR-Cas9 Potential

TIPRANKS
·
Oct 27

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

GlobeNewswire
·
Oct 27

Crispr Therapeutics AG Faces Stock Price Slump

TIPRANKS
·
Oct 25

H.C. Wainwright Remains a Buy on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Oct 22

AI Biotech Stocks Shined. Recursion Up 15%; Beam Up 14%; Tempus Up 7%; Novavax Up 6%; Crispr And Ginkgo Up 4%; Hims Up 2%

Tiger Newspress
·
Oct 20

BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $93 From $78, Maintains Buy Rating

MT Newswires Live
·
Oct 17

Crispr Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Oct 17

Crispr Therapeutics price target raised to $93 from $78 at BofA

TIPRANKS
·
Oct 17